Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2015-003817-31 | EudraCT Number | ||
| 55375515EDI1001 | Other Identifier | Janssen Research & Development, LLC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of JNJ-55375515 in healthy participants after administration of single and multiple oral doses.
This is a randomized (study medication assigned to participants by chance), double-blind (neither the investigator nor the participants know what treatment the participant is receiving), placebo-controlled (an inactive comparator treatment that has no study drug in it), single center study in healthy male participants and female participants of non-childbearing potential (surgically sterile or post menopausal), aged 18 to 58 years inclusive. This study will consist of two parts; a Single Ascending Dose (SAD) part and a Multiple Ascending Dose (MAD) part. The SAD will consist of 6 escalating dose cohorts. Participants in each cohort will be randomized to receive a single oral administration of JNJ-55375515 or placebo after an overnight fast. The planned doses of JNJ-55375515 range from 0.75 to 100 milligrams (mg). Participants in an additional cohort will be dosed in the fed state to determine the effects of food on the safety, tolerability and pharmacokinetics of JNJ-55375515. An additional optional cohort may be evaluated to further explore the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-55375515, with the maximal dose not exceeding 200 mg. The study duration for participants in the SAD part of the study will be approximately 2 to 5.5 weeks, including eligibility Screening. The MAD will consist of 3 cohorts of 9 participants. Participants will receive once daily oral doses of JNJ-55375515 or placebo for 10 consecutive days. The study duration for participants in the MAD part of this study will be approximately 3 to 7 weeks including the eligibility Screening. The Safety of Participants will be monitored throughout the study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part 1: Single Ascending Dose (SAD) | Experimental | Participants will receive 0.75 milligrams (mg) of JNJ-55375515 (starting dose) or Placebo on Day 1. Dose of the study medication will be escalated sequentially up to a maximum of 200 mg. |
|
| Part 2: Multiple Ascending Dose (MAD) | Experimental | Participants will receive JNJ-55375515 (at doses determined based on the data from the SAD part) or Placebo from Day 1 to 10. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| JNJ-55375515 | Drug | Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants with Adverse Events | An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. | Up to Day 7 after discharge |
| Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) | The Tmax is defined as actual sampling time to reach maximum observed concentration. | Up to Day 5 |
| Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t]) | The AUC(0-t) is the area under the plasma concentration-time curve from time zero to any time 't'. | Up to Day 5 |
| Part 1: Elimination Half-Life (t1/2) | The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z). | Up to Day 5 |
| Part 1: Maximum Observed Plasma Concentration (Cmax) | The Cmax is the maximum observed concentration. | Up to Day 5 |
| Part 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) | The Tmax is defined as actual sampling time to reach maximum observed concentration. | Up to Day 15 |
| Part 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t]) |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Tolerated Dose (MTD) of JNJ-55375515 | The maximum tolerated dose is defined as the dose below the dose at which 2 or more subjects receiving the same dose of active study drug experience the same dose-limiting toxicity or have the same severe adverse event, or below the level at which the Investigator and Sponsor agree that an unacceptable dose-limiting toxicity has occurred in a single subject treated with active study drug. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Merksem | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Participants will receive matching placebo. |
|
The AUC(0-t) is the area under the plasma concentration-time curve from time zero to any time 't'. |
| Up to Day 15 |
| Part 2: Elimination Half-Life (t1/2) | The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z). | Up to Day 15 |
| Part 2: Maximum Observed Plasma Concentration (Cmax) | The Cmax is the maximum observed concentration. | Up to Day 15 |
| Up to Day 5 in part 1; up to Day 15 in part 2 |
| Part 1: The Effect of Food on the Number of Adverse Events | Baseline up to Day 5 |
| Part 1: The Effect of Food on Maximum Observed Plasma Concentration (Tmax) | Baseline up to Day 5 |
| Part 1: The Effect of Food on Maximum Observed Plasma Concentration (Cmax) | Baseline up to Day 5 |
| Part 1: The Effect of Food on Elimination Half-Life (t1/2) | Baseline up to Day 5 |
| Part 1: The Effect of Food on Area Under the Plasma Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t]) | Baseline up to Day 5 |